Braveheart Bio, Inc.

BRVE

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

19.38 0.24 −1.22%
Market cap
$1.8B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−28.7%
Net debt / EBITDA
1.3×
Payout ratio
—

Where the cash went Fiscal 2025, year to 31 December 2025

Free cash flow was −$2.0M: capital expenditures were more than operating cash flow. Cash rose by $89.2M. Lines the picture does not name came to −$33.6M. What is a cash flow statement?

Free cash flow
−$2.0M
Returned to shareholders
$0.00
Debt, net
$0.00 borrowed
Change in cash
+$89.2M over the period
Where the cash went, in billions of dollars
Operating cash flow0.0
Free cash flow0.0
Shares issued, net+0.1
Other0.0
Change in cash0.1

Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Dec '25
Net Income
(66.05)
Non Cash Items (Other)
62.42
Accounts Payable Change
0.90
Change in payables and accrued liability
0.91
Change in other assets and liabilities
(0.19)
Operating Cash Flow
(2.01)
Other investing activities
(33.57)
Investing cash flow
(33.57)
Equity Repurchase (Common, Net)
0.10
Equity Repurchase (Preffered, Net)
124.65
Financing cash flow
124.74
Change in Cash
89.16
Ending Cash
89.16
Stock Based Compensation
0.18
Dividends Paid (Common)
0.00
Assets Liabilities Change (Total)
1.62
Issuance/Purchase of Shares
124.74
Other line items
Revenue per Employee
0.00

Fold the line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 12 Nov 2026